
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
National report — The first-ever study attempting to assess the total burden of skin disease indicates that the toll exacted from Americans has been underestimated.